Targeting NSCLC with Precision: Evaluation of the Emerging Role of Antibody-Drug Conjugates - Episode 14
Challenges and Learnings from EVOKE-01
Benjamin Levy, MD, provides an overview of the rationale and study design for the EVOKE-01 trial, which evaluates the efficacy and safety of sacituzumab govitecan in patients with non-small cell lung cancer who have experienced disease progression following treatment with platinum-based chemotherapy and checkpoint inhibitors.
- Please review the rationale and study design for EVOKE-01 evaluating sacituzumabgovitecan in patients with NSCLC with disease progression following platinum-based chemotherapy and checkpoint inhibitors. (Garassino, et al. ASCO 2022. Abstract TPS9149)
- Briefly outline the study design and key endpoints.
- Jan 2024 Press Release; Phase 3 EVOKE-01 study did not meet its primary endpoint of overall survival (OS) in previously treated metastatic non-small cell lung cancer (NSCLC)
- ASCO 2024 Data: Sacituzumab govitecan (SG) vs docetaxel (doc) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC) previously treated with platinum (PT)-based chemotherapy (chemo) and PD(L)-1inhibitors (IO): Primary results from the phase 3 EVOKE-01 study